Literature DB >> 1575586

Staphylococcal infections in childhood dermatomyositis--association with the development of calcinosis, raised IgE concentrations and granulocyte chemotactic defect.

E C Moore1, F Cohen, S D Douglas, V Gutta.   

Abstract

There is a high incidence of staphylococcal infection in children with dermatomyositis, which is limited to those children who either already have or subsequently develop calcinosis. Of 15 children followed up for 3-10 years after diagnosis, all nine who developed calcinosis had infections with Staphylococcus aureus compared with none of six without calcinosis. Of these nine, the occurrence of staphylococcal infections before calcinosis was observed in four, suggested by history in two, and unclear in three children. Granulocyte chemotaxis to Staphylococcus aureus was more severely depressed in those children with calcinosis, whereas those without calcinosis did not differ significantly from controls. The chemotactic defect was due to a serum factor (patients' serum depressed control chemotaxis and control serum corrected the patients' chemotaxis). The nine children with calcinosis also had significantly higher serum IgE concentrations than non-atopic age matched controls; the six without calcinosis did not differ from controls. The increased IgE concentrations appeared to develop after staphylococcal infection and before calcinosis. Two of five patients with calcinosis had increased antistaphylococcal IgE antibodies; neither of the two patients without calcinosis had such increased antibodies. This suggests preceding immunological differences in patients with dermatomyositis who do and do not subsequently develop calcinosis, either increasing susceptibility to Staphylococcus aureus infection or potentially resulting from such infections.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1575586      PMCID: PMC1004666          DOI: 10.1136/ard.51.3.378

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  30 in total

1.  Familial neutrophil chemotaxis defect, recurrent bacterial infections, mucocutaneous candidiasis, and hyperimmunoglobulinemia E.

Authors:  R E Van Scoy; H R Hill; R E Ritts; P G Quie
Journal:  Ann Intern Med       Date:  1975-06       Impact factor: 25.391

2.  The hyperimmunoglobulin E syndrome--a neutrophil chemotactic defect reversible by histamine H2 receptor blockade?

Authors:  H Mawhinney; M Killen; W A Fleming; A D Roy
Journal:  Clin Immunol Immunopathol       Date:  1980-12

3.  Cimetidine in the treatment of hyperimmunoglobulinemia E with impaired chemotaxis.

Authors:  G L Simon; H G Miller; S J Scott
Journal:  J Infect Dis       Date:  1983-06       Impact factor: 5.226

4.  Elevated levels of chemotaxis inhibitory activity in sera of patients with systemic lupus erythematosus.

Authors:  S Hasegawa; T Baba; Y Koitabashi; Y Shimizu; H Sonozaki; Y Hori; S Nishiyama
Journal:  J Dermatol       Date:  1980-10       Impact factor: 4.005

5.  Plasma exchange therapy of a childhood onset dermatomyositis patient.

Authors:  E J Brewer; E H Giannini; R D Rossen; B Patten; E Barkley
Journal:  Arthritis Rheum       Date:  1980-04

6.  Immunoglobulin E anti-Staphylococcus aureus antibodies in atopic patients.

Authors:  G A Walsh; K L Richards; S D Douglas; M N Blumenthal
Journal:  J Clin Microbiol       Date:  1981-06       Impact factor: 5.948

7.  Leukocyte locomotion and regulative serum effects in rheumatoid arthritis.

Authors:  G Lanzer; C Zielinski; W Knapp; R Eberl; C Steffen
Journal:  Z Rheumatol       Date:  1981 Mar-Apr       Impact factor: 1.372

8.  Calcinosis in dermatomyositis treated with probenecid.

Authors:  E Skuterud; O A Sydnes; T K Haavik
Journal:  Scand J Rheumatol       Date:  1981       Impact factor: 3.641

9.  Chemotaxis of polymorphonuclear leukocytes from patients with rheumatoid arthritis.

Authors:  A G Mowat; J Baum
Journal:  J Clin Invest       Date:  1971-12       Impact factor: 14.808

10.  Defective polymorphonuclear leucocyte chemotaxis in rheumatoid arthritis associated with a serum inhibitor.

Authors:  S M Hanlon; G S Panayi; R Laurent
Journal:  Ann Rheum Dis       Date:  1980-02       Impact factor: 19.103

View more
  8 in total

Review 1.  Morbidity and mortality in adult polymyositis and dermatomyositis.

Authors:  Isabelle Marie
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

Review 2.  Laboratory evaluation of the inflammatory myopathies.

Authors:  L G Rider; F W Miller
Journal:  Clin Diagn Lab Immunol       Date:  1995-01

Review 3.  Calcinosis Biomarkers in Adult and Juvenile Dermatomyositis.

Authors:  Melody P Chung; Carrie Richardson; David Kirakossian; Amir B Orandi; Lesley A Saketkoo; Lisa G Rider; Adam Schiffenbauer; Carlos A von Mühlen; Lorinda Chung
Journal:  Autoimmun Rev       Date:  2020-03-28       Impact factor: 9.754

4.  Hyperimmunoglobulin E-recurrent infection syndrome in a patient with juvenile dermatomyositis.

Authors:  J K Min; M L Cho; S C Kim; Y S Lee; S H Lee; S H Park; Y S Hong; C S Cho; H Y Kim
Journal:  Korean J Intern Med       Date:  1999-01       Impact factor: 2.884

5.  Juvenile dermatomyositis in South African children is characterised by frequent dystropic calcification: a cross sectional study.

Authors:  Gail Faller; Bhadrish J Mistry; Mohammed Tikly
Journal:  Pediatr Rheumatol Online J       Date:  2014-01-07       Impact factor: 3.054

6.  Inpatient burden of juvenile dermatomyositis among children in the United States.

Authors:  Michael C Kwa; Jonathan I Silverberg; Kaveh Ardalan
Journal:  Pediatr Rheumatol Online J       Date:  2018-11-13       Impact factor: 3.054

Review 7.  Panniculitis, infection, and dermatomyositis: case and literature review.

Authors:  Miltiadis Douvoyiannis; Nathan Litman; Alina Dulau; Norman T Ilowite
Journal:  Clin Rheumatol       Date:  2009-04-10       Impact factor: 3.650

Review 8.  The Vasculopathy of Juvenile Dermatomyositis.

Authors:  Charalampia Papadopoulou; Liza J McCann
Journal:  Front Pediatr       Date:  2018-10-09       Impact factor: 3.418

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.